Table 1.

Patient characteristics

	N = 49 (%)
Age (median(range))	68 (35–82)
Gender
Female	7 (14%)
Male	42 (86%)
Disease
Locally advanced	13 (27%)
Metastatic	36 (73%)
Treatment
Cisplatin-gemcitabine	24 (49%)
Carboplatin-gemcitabine	3 (6%)
Pembrolizumab	20 (41%)
Vinflunine	2 (4%)
Completed cycles (median(range))	4 (1–6)
Completion of planned treatment
Yes	22 (45%)
No	27 (55%)
Hospital admission during treatment
Yes	27 (55%)
No	22 (45%)